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Mesenchymal stem cells (MSC) have been shown to possess immunomodulatory properties 
that highlight their potential as a cellular therapy for autoimmune disease. We propose to 
examine the in vitro potential of stem cells derived from umbilical cord tissue to suppress the 
effector functions of human auto-reactive T cells. While the mechanism(s) of suppression of T 
cell function are not fully understood, it has been hypothesized that MSC-derived 
immunosuppressive soluble factors and cell-to-cell contact are important. We developed an in 
vitro culture assay to assess the effects of umbilical cord derived MSC (TC-MSC) on T cell 
function. Various doses of low-passage TC-MSCs were adhered to collagen-coated 96 well 
plates or in the lower chamber wells of transwell plates. HLA-matched EBV transformed B cells 
were pulsed +/- with appropriate autoantigenic peptide and cultured with adherent MSC or in the 
upper transwell chambers with the appropriate T cell clone. After 48 hours, cells were stained 
for CD4 and stained intracellularly for IFN-γ and analyzed by flow cytometry. We observed 
decreased T cell effector function with MSC co-culture and this was partially restored by 
separation of MSC and T cell+B cell+peptide in the transwell. We examined if prostaglandin E2 
derived from the MSC also contributed to decreased T cell effector function. The inclusion of a 
COX-2 inhibitor in the culture system led to partially restored T cell effector function. We 
conclude that TC-MSC-derived soluble factor(s) and TC-MSC:T cell contact both contribute to 
the TC-MSC’s immunosuppressive effects. Primary TC-MSC isolates (with no prior cell culture) 
will also be tested in this system to determine if they possess similar immunosuppressive effects 
as adherent, cultured TC-MSC. These studies will pinpoint the functional mechanisms of the 
TC-MSC immunomodulatory properties on T cell effector function and may suggest avenues of 
enhancing MSC function in the treatment of autoimmune disease.  
 
                                                         
